*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Medlive Technology Co., Ltd.**
**醫脈通科技有限公司**
*(Incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 2192)**

# ADOPTION OF REVISED DIVIDEND POLICY

This announcement is made by Medlive Technology Co., Ltd (the "**Company**", which together with its subsidiaries, shall be referred to as the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the existing dividend policy of the Company set out on page 112 of the 2025 annual report of the Company released on the HKExnews website on 21 April 2026 (the "**Existing Dividend Policy**"). The board of directors (the "**Board**") of the Company announces that it has approved and adopted the revised dividend policy (the "**Revised Dividend Policy**") which shall supersede the Existing Dividend Policy with effect from 18 November 2026 as follows:

The Company has adopted a dividend policy which is in accordance with the relevant provisions of its articles of association. Pursuant to the dividend policy, the Company aims to maximize returns to Shareholders and may from time to time declare dividends in any currency to be paid to the members of the Company but no dividend shall be declared in excess of the amount recommended by the Board. No dividend shall be declared or payable except out of the profits and reserves of the Company lawfully available for distribution. No dividend shall carry interest against the Company. The Company may distribute dividends by way of cash or by other means that the Board considers appropriate, based on various factors such as the Company's results of operations, cash flows, financial condition, shareholders' interests, capital requirements, payment to the Company of cash dividend by its subsidiaries and other factors that may be relevant.

For each of the three financial years ending 31 December 2026, 2027 and 2028, the Company plans to distribute dividends (final and interim dividends in aggregate) representing not less than 80% of the Company's profit for the year attributable to owners of the parent for that year.

The Company will continue to re-evaluate its dividend policy. All dividend decisions made by the Board will be made in accordance with the dividend policy as explained above.

The payment of dividend is subject to compliance with applicable laws and regulations including the laws of the Cayman Islands and the articles of association of the Company. The Board will review its dividend policy from time to time in light of its operation needs, earnings, financial condition, working capital requirements and future business plans as the Board may deem relevant at such time and may exercise its sole and absolute discretion to update, amend and/or modify the dividend policy at any time as it deems fit and necessary. There can be no assurance that dividends will be paid in any particular amount for any given period.

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board
**Medlive Technology Co., Ltd.**
**Tian Liping**
*Chairwoman and Chief Executive Officer*

Hong Kong, 18 November 2026

*As at the date of this announcement, the Board comprises Ms. Tian Liping, Mr. Tian Lixin, Mr. Tian Lijun and Ms. Zhou Xin as executive Directors; Mr. Eiji Tsuchiya and Mr. Kazutaka Kanairo as non-executive Directors; and Mr. Richard Yeh, Dr. Ma Jun and Ms. Wang Shan as independent non-executive Directors.*